recombinant salmon calcitonin

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Forcaltonin has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 20/11/2008

Authorisation details

Product details
Agency product number
Active substance
Recombinant salmon calcitonin
International non-proprietary name (INN) or common name
recombinant salmon calcitonin
Therapeutic area (MeSH)
  • Hypercalcemia
  • Osteitis Deformans
  • Bone Resorption
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Unigene UK Ltd.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Unigene UK Limited
191 Sparrows Herne
Bushey Heath
Hertfordshire WD23 1AJ
United Kingdom

Product information

20/11/2008 Forcaltonin - EMEA/H/C/000197 - IA/0015

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Calcium homeostasis

Therapeutic indication

Calcitonin is indicated for:
Prevention of acute bone loss due to sudden immobilisation such as in patients with recent
osteoporotic fractures
Paget's disease
Hypercalcaemia of malignancy

Assessment history

How useful was this page?

Add your rating